TTS Pharma Limited Announces Closing of £10.3 Million Fundraising and New Board Appointment
23.5.2019 09:00:00 EEST | Business Wire | Press release
COMPLETION OF SERIES B FUNDRAISE
TTS Pharma Limited (“TTS Pharma” or the “Company”), a UK company which is a vertically integrated supply chain manager in the cultivation, manufacturing and development of the emerging ethical cannabis market, announces that it has successfully closed a private equity investment totalling £10.3 million, on the basis of a two-tranche investment. This investment will permit TTS Pharma to become one of the leading global suppliers in this fast-growing multibillion-dollar industry, by allowing it to expand its existing supply chain, develop its own facilities and further strengthen its academic and commercial partnerships. It also enables the Company to advance its diversified operations in the wellness, nutraceutical and pharmaceutical sectors. The ethical cannabis market is set to become a high growth, disruptive and innovative new segment in the life sciences field and TTS Pharma is ideally positioned to capture rapid value within this market.
BOARD UPDATE
TTS Pharma also announces the appointment of a new Executive Chairman, Paul Atherton, who brings with him Global Institutional and Public Market experience to the board.
TTS Pharma is a unique business with core competencies and partners in drug discovery, development, separation, purification and drug delivery, incorporating the supply chain management of cannabinoids, such as CBD. It is intending to provide a transparent and accountable supply chain that produces legal and regulated cannabis-derived active agents for R&D, Bulk Active ingredients and wholesale distribution of finished goods. TTS Pharma is committed to producing the highest quality, fully compliant CBD products for use in a large range of commercial segments, alongside a number of partners, after obtaining the requisite regulatory clearance.
The pre-established supply chain including both domestic and international partners enables the Company to legally supply various CBD products to a growing range of customers. In mid-2018, TTS Pharma commenced a comprehensive R&D sponsorship programme to extract the various cannabinoids, and then to consider their chemical properties and effects, in order to develop new products in both human and animal markets.
Paul Atherton commented:
“I am delighted to join TTS Pharma as Executive Chairman. Utilising existing in-house know-how, TTS Pharma represents a unique chance to develop and produce world class, novel products for the rapidly growing new industry of ethically-based, legal cannabis products. I see a long-term opportunity to establish cost and scale advantages, allowing this Company to flourish in this attractive, global emerging industry.”
TTS Pharma CEO, Mark Tucker added:
“It is a great privilege to lead a team of highly experienced pharmaceutical professionals building an exciting portfolio of technologies and products based on world class expertise and industry leading know-how. We are well placed to build on the scientific developments driving this rapidly growing industry and provide cannabinoid products of unparalleled quality and consistency. Since my early involvement in pre-clinical cannabinoid trials in 2003, TTS Pharma has grown extensively and is now producing and developing a range of innovative and safe cannabis-based products within existing legislation and the evolving regulatory framework.”
About Paul Atherton
Paul Atherton was until the end of 2017, the Chief Executive Officer and Chief Financial Officer of Heritage Oil Limited, which held both production and exploration assets around the world. The company was one of the largest oil and gas companies listed on the Main Board of the London Stock Exchange and a member of the FTSE 250, before being taken private for US$1.6 billion in 2014. During this time Paul executed significant fundraisings, mergers and acquisitions and the eventual privatisation, generating outstanding shareholder returns. Paul is a Chartered Accountant having qualified at Deloitte and worked in corporate finance at BDO.
About TTS Pharma Ltd
TTS Pharma is a private company, incorporated in England and Wales and established in 2012, with offices in London and Liverpool. The Company has an R&D business developing products and holds deep industry expertise in extraction, separation and manufacturing of Cannabinoids. The Company has begun sales of its highly purified cannabis related products and technologies. The company abides by all legal and regulatory requirements in the UK and elsewhere and expects to gain further permissions related to these products in due course.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190522005683/en/
Contact information
Enquiries to:
TTS Pharma Ltd
Mark Tucker, CEO
mrtucker@ttspharma.com
Paul
Atherton, Chairman
patherton@ttspharma.com
Sciad
Communications Ltd
Maria Patey
TTSPharma@sciad.com
+44
203 7550571
Corporate Broker and Financial Advisor
The
Life Sciences Division Ltd
Ms Alia Minhas MBA ACSI
ali@thelifesciencesdivision.com
+44
207 8741890
Dr. Navid Malik. PhD, MSc, MBA, ACSI
navid@thelifesciencesdivision.com
+44
207 8741890
Legal Advisor
Osborne Clarke LLP
Dr
Janita Good, Partner Head of Lifescience and Healthcare
janita.good@osborneclarke.com
+44
207 1057042
M&A Advisor
ThinkingLinking
Mark
Dixon, Chief Thinking Officer
mdixon@thinkinglinking.com
+44
207 5561093
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H2SITE Secures New Strategic Investment to Accelerate Industrial Deployment of Hydrogen Production and Separation Solutions25.6.2026 07:00:00 EEST | Press release
H2SITE, a leading industrial company in hydrogen production and separation solutions, has completed a second closing of its Series B round. The transaction brings in EIC Fund with a private investor who will support the company’s next phase of growth and increases H2SITE’s total funding raised in this round to more than €42 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624444396/en/ H2SITE These new partners, join BEV, Suma Capital, Hy24, Crane, Enagás Emprende, Calderion and CRPV who participated in the first closing, further validating the confidence of the European innovation ecosystem in H2SITE’s ability to industrialize and deploy key hydrogen solutions at commercial scale. Over the past years, H2SITE has successfully demonstrated the maturity and scalability of its technology, achieving more than 50,000 operating hours with its membrane reactors and separators, establishing advanced manufacturing capabilit
FPT Expands Strategic Collaboration with Microsoft to Advance AI Frontier Innovation Across Asia25.6.2026 05:00:00 EEST | Press release
FPT Corporation today announced an expanded strategic collaboration with Microsoft aimed at accelerating enterprise AI adoption and co‑innovation across Asia, with a strong focus on ASEAN, Japan, and South Korea. The collaboration brings together Microsoft’s global AI platforms with FPT’s large‑scale delivery and regional market capabilities to support organizations as they move from AI experimentation to real‑world, scalable impact, with measurable business outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624200416/en/ Representatives of FPT and Microsoft at the signing ceremony, formalizing an expanded strategic collaboration to advance AI Frontier innovation across Asia The collaboration aligns with FPT’s AI‑First strategy and Microsoft’s vision for human‑agent collaboration, with the goal of enabling enterprises to redesign how work is done across engineering, operations, and business functions. Positioning FP
Murata Expands Product Information Management API Service to Cover All 73 Product Categories25.6.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) now covers all 73 product categories in its Product Information Management (PIM) API Service. By using this API service, engineers, developers, and procurement specialists can retrieve up-to-date product information, enabling prompt responses to product status changes and reducing the risk of component obsolescence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624146819/en/ [Murata Manufacturing Co., Ltd.] Murata expands Product Information Management API Service to cover all 73 product categories As digital transformation accelerates in the manufacturing industry, a wide variety of systems and platforms are being used across the entire workflow - from design and component selection through to procurement. Previously, Murata’s PIM API Service covered only surface-mount and leaded ceramic capacitors and inductors. This narrow service coverage required user
Swedish Court Further Reschedules Delivery of Judgment in PriceRunner Vs Google Antitrust Case24.6.2026 21:55:00 EEST | Press release
Klarna Group plc (NYSE: KLAR) wishes to update investors that the Patent and Market Court in Stockholm, Sweden (Patent- och marknadsdomstolen) has again postponed publication of its judgment in the antitrust damages proceedings brought by PriceRunner, a Klarna subsidiary, against Google. The Court has rescheduled publication of its judgment from June 26, 2026 to July 1, 2026 at 13:00 CET. As with the Court's two previous notifications, the rescheduling is a procedural decision by the Court and relates solely to the timing of the judgment delivery. In its notification, the Court cited high workload as the reason for needing additional time to finalize the judgment. No inference about the outcome should be drawn from it. Important Notice The outcome of the proceedings is inherently uncertain. No assurance can be given that PriceRunner will succeed on liability or quantum. Any award would be subject to appeal by Google, to sharing arrangements with former PriceRunner shareholders and Klar
Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project24.6.2026 17:00:00 EEST | Press release
Vertex Energy, Inc. (“Vertex” or the “Company”) today announced it is advancing a project at its Mobile, Alabama refinery to produce crude-derived conventional Group III base oils through the Company’s existing hydrocracker and related processing infrastructure, providing lubricant manufacturers and blenders with an additional domestic source of high-quality Group III supply. The project is designed to add an incremental 6,000 barrels per day of conventional Group III production capacity and support production of 4 cSt, 6 cSt, and 8 cSt Group III base oils using an existing crude-derived hydrocracked vacuum gas oil stream produced at the Company’s Mobile, Alabama refinery. Combined with the Company’s existing re-refined Group III base oil production, this additional capacity is expected to make Vertex the leading Group III producer in North America. Vertex has completed preliminary design work and has procured a high-pressure lubricants hydrotreating unit. The Company plans to start pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom